

CALL FOR ABSTRACTS

★ **Abstract Submission Deadline:** November 19, 2020

★ **Late-Breaking and Clinical Trials
Abstract Submission Deadline:** January 11, 2021



Continuing Medical Education Activity -
AMA PRA Category 1 Credits™ available

AACR

American Association
for Cancer Research™

ANNUAL MEETING

APRIL 9-14, 2021

WASHINGTON ★ DC
#AACR21

★ ★ ★ ★ ★ ★ ★

AACR.ORG ★ #AACR21



DISCOVERY
SCIENCE
DRIVING
CLINICAL
BREAKTHROUGHS

AACR

American Association
for Cancer Research®

ANNUAL MEETING

APRIL 9-14, 2021

WASHINGTON ★ DC
#AACR21



DISCOVERY
SCIENCE
DRIVING
CLINICAL
BREAKTHROUGHS

AACR OFFICERS

President

Antoni Ribas

President-Elect

David A. Tuveson

Treasurer

William N. Hait

Immediate Past President

Elaine R. Mardis

Chief Executive Officer

Margaret Foti

Board of Directors

Adriana Albini

Scott A. Armstrong

René Bernards

Marcia R. Cruz-Correa

Keith T. Flaherty

Silvia Chiara Formenti

Elaine Fuchs

Roy S. Herbst

Carl H. June

Karen E. Knudsen

Edison T. Liu

Ira Mellman

Martine F. Roussel

Charles Swanton

Suzanne L. Topalian

TABLE OF CONTENTS

2	Key Dates
3	Welcome
4	Scientific Program <ul style="list-style-type: none">Plenary SessionsMajor SymposiaAdvances SessionsForumsEducational Program
8	Policy Sessions
9	Spotlight on Clinical Trials
10	Professional Advancement Opportunities
11	Continuing Medical Education (CME)
12	Survivor and Patient Advocacy Program
13	Press Coverage and Social Media
14	Financial Support for Attendance
16	Guidelines for Preparation and Submission of Abstracts
19	Abstract Categories
24	AACR Membership Opportunities
26	General Information
28	Annual Meeting Committees

ABOUT THE COVER IMAGE:

©2020 American Association for Cancer Research


Inside of sphere (*clockwise*): AACR Virtual Special Conference:
Epigenetics and Metabolism art; Glioblastoma (iStock); DNA sequencing (Getty)

Foreground of sphere (*clockwise*): 3D render of T cells attacking cancer cells (Getty);
3D illustration of a method of DNA sequencing (Getty); Medical 3D illustration of a
dividing cancer cell (Getty)

AACR ANNUAL MEETING 2021 KEY DATES



September 30, 2020	Abstract Submission Opens
October 13, 2020	Application Deadline: NextGen Stars
November 12, 2020	Membership Application Deadline for Regular Abstract Sponsors and Scholar-in-Training Award Applicants
November 19, 2020	Regular Abstract Submission Deadline (11:59 p.m. ET)
November 19, 2020	Application Deadlines: AACR Global Scholar-in-Training Awards AACR Minority-Serving Institution Faculty Scholar in Cancer Research Awards AACR Minority Scholar in Cancer Research Awards AACR Scholar-in-Training Awards AACR Women in Cancer Research Scholar Awards
December 18, 2020	Late-Breaking and Clinical Trials Abstract Submission Opens
January 6, 2021	Online Itinerary Planner Available
January 7, 2021	Membership Application Deadline for Late-Breaking and Clinical Trials Abstract Sponsors
January 11, 2021	Late-Breaking and Clinical Trials Abstract Submission Deadline (11:59 p.m. ET)
February 1, 2021	Regular Abstract Status Notifications Sent
February 4, 2021	Submission Deadline: Final Data for Clinical Trial Placeholder Abstracts
February 10, 2021	Late-Breaking and Clinical Trials Abstract Notifications Sent
February 22, 2021	Regular Abstract Withdrawal Deadline
March 9, 2021	Late-Breaking and Clinical Trials Abstract Withdrawal Deadline
March 17, 2021	Annual Meeting App Available for Download
April 9, 2021	AACR Annual Meeting Begins (12:00 p.m. ET)
April 9, 2021	Late-Breaking and Clinical Trials Abstract Texts Posted to Online Itinerary Planner and Meeting App



AACR ANNUAL MEETING 2021 WELCOME



Dear Members and Friends of the AACR,

We are pleased to announce the Call for Abstracts for the 112th Annual Meeting of the American Association for Cancer Research (AACR). Reflecting the theme of this year's meeting, "Discovery Science Driving Clinical Breakthroughs," the scientific program will span the broad spectrum of cancer science and medicine from basic, translational, and clinical research including cancer health disparities; to early detection, interception, prevention, and population science; to regulatory science and policy.

The Opening Plenary Session will address the theme of the meeting and will include presentations on lineage tracing of tumor metastasis, tumor metabolism, genomic sequencing in diverse populations, immune surveillance, antitumor immune response, and clinical implications. New this year is the Discovery Science Plenary Session, which will focus on the mechanisms, impact, and exploitation of cancer chromosomal instability for potential therapeutic intervention. Also, a comprehensive educational program of more than 60 educational sessions and methods workshops, covering a wide array of disciplines and new technologies, is currently under development.

Major progress against cancer has been realized over the past few decades due to remarkable scientific advances and multidisciplinary collaborations, and during this year a record number of new cancer treatments were approved by the U.S. Food and Drug Administration. However, during the COVID-19 pandemic, many labs were forced to close, and clinics have needed to shift resources and refocus efforts to combat this enormous public health crisis. There is now much concern that the delays in cancer screening, diagnosis, and treatment because of the COVID-19 pandemic will have a significant negative impact on the pace of progress against cancer and on cancer patient outcomes. Now more than ever it is critically important to focus our collective efforts and resources on our mission to prevent and cure all cancers.

Despite these challenges, this has been a transformative year for the global cancer research community – one that has resulted in a new wave of scientific innovation that will be reflected in our Annual Meeting program. The year 2021 will be an exciting time for us to celebrate the 50th Anniversary of the signing of the National Cancer Act. The signing of this Act was a pivotal moment in history, as it has led to the formation of highly impactful comprehensive cancer centers in the U.S., the development of education and training programs for early-career laboratory and clinical investigators, increased funding for innovative cancer research, and many cancer breakthroughs that have saved millions of lives from the disease.

Proffered oral and poster presentations selected from submitted abstracts are a vital part of our Annual Meeting. For your interest, a new abstract category for research on COVID-19 and cancer has been added to our Call for Abstracts. We look forward to receiving your submissions and to providing an interactive venue for you to share your important work. Your participation in the 2021 Annual Meeting will not only be a welcome addition to the program, but it will also maximize collaborations, stimulate creative thinking about how to accelerate progress against cancer, and contribute greatly to the cause.

The regular abstract deadline is November 19, 2020. Our proffered program also features special oral presentation opportunities in several Clinical Trial Plenary Sessions for abstracts reporting on high-impact clinical trials. The deadline for late-breaking abstracts and clinical trial abstracts is January 11, 2021.

Please note that recently, the AACR Board of Directors approved an expansion of the abstract sponsorship privileges for certain AACR member types. We encourage AACR members to use their additional privileges to sponsor abstract submissions from their mentees and nonmember colleagues. Please view the details of these expanded privileges on page 18.

The AACR will also continue to offer special presentation opportunities for early-career scientists. All AACR Associate Members, as well as Active Members at the assistant professor level or equivalent, may apply to the NextGen Stars Program to be considered for the honor of presenting their work in one of the major sessions during the meeting. Interested members must submit an abstract along with supporting materials by October 13, 2020. Please check the AACR website (AACR.org/AACR2021) regularly for program updates and other meeting announcements.

During these difficult times our heartfelt sympathies are extended to everyone who has been impacted by this global health crisis. It is our sincere hope that we will all be able to gather in person in 2021 to discuss your innovative work across the full spectrum of cancer research.

We look forward to receiving your abstract submissions and to your active participation in AACR Annual Meeting 2021.


With best wishes and regards,

Antoni Ribas, MD, PhD, FAACR
President, 2020-2021

Charles Swanton, FRCP, BSc, PhD, FAACR
Chair, 2021 Program Committee



AACR ANNUAL MEETING 2021
SCIENTIFIC PROGRAM



WHY YOU SHOULD ATTEND THE WORLD'S MOST IMPORTANT CANCER RESEARCH MEETING

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world. This meeting presents the many scientific discoveries across the breadth of cancer research—from prevention, early detection, and interception; to cancer biology and genetics, translational, and clinical studies; to survivorship, population science, and advocacy. You will be exposed to the latest developments in all areas of cancer research, form new collaborations, and learn how to apply exciting new concepts, tools, and techniques to your own research.

This year's program, with the theme of "Discovery Science Driving Clinical Breakthroughs," will be a comprehensive, cutting-edge scientific event that you will not want to miss!

PROGRAM IN PROGRESS

Beginning at 3:00 p.m. on Friday, April 9, and continuing until 3:30 p.m. on Saturday, April 10, 2021, a program of Educational Sessions and Methods Workshops will be presented. An Educational Program Pass granting access to the complete educational program will be available for purchase when registration opens. On Saturday at 3:45 p.m. an exciting new Discovery Science Featured Plenary Session will be open to all registrants. The Opening Ceremony and the Opening Plenary Session will take place on Sunday morning, April 11. The meeting will conclude at 1:30 p.m. on Wednesday, April 14. Abstracts submitted for the regular (November 19, 2020) or late-breaking and clinical trials (January 11, 2021) submission deadlines will be considered for short talks or ePoster presentations. The 2021 Program in Progress follows; additional exciting and timely invited sessions are being developed and will be posted at AACR.org/AACR2021.

PLENARY SESSIONS

Saturday, April 10, 2021

DISCOVERY SCIENCE PLENARY SESSION: MECHANISMS, IMPACT, AND EXPLOITATION OF CANCER CHROMOSOMAL INSTABILITY

David Pellman, Dana-Farber Cancer Institute, Boston, MA

Angelika Amon, Massachusetts Institute of Technology, Cambridge, MA

Stephen P. Jackson, University of Cambridge, Cambridge, United Kingdom

Additional speaker to be announced.

Sunday, April 11, 2021

OPENING PLENARY SESSION: DISCOVERY SCIENCE DRIVING CLINICAL BREAKTHROUGHS

Chair: Charles Swanton, The Francis Crick Institute, London, United Kingdom

Jonathan S. Weissman, University of California, San Francisco, CA

Karen H. Vousden, The Francis Crick Institute, London, United Kingdom

Matthew G. Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA

Melissa B. Davis, Weill Cornell Medical College, New York, NY

Mark A. Dawson, Peter MacCallum Cancer Centre, Melbourne, Australia

Zhijian James Chen, UT Southwestern Medical School, Dallas, TX

AACR ANNUAL MEETING 2021 SCIENTIFIC PROGRAM

Plenary Sessions (cont'd)

Monday, April 12, 2021

UNDERSTANDING THE MOLECULAR AND MICROENVIRONMENTAL DETERMINANTS OF CANCER

Chair: Christina Curtis, Stanford University,
Stanford, CA

Garry P. Nolan, Stanford University School of Medicine,
Stanford, CA

Serena Nik-Zainal, University of Cambridge,
Cambridge, United Kingdom

Ross L. Levine, Memorial Sloan Kettering Cancer
Center, New York, NY

Jérôme Galen, INSERM, Paris, France

Tuesday, April 13, 2021

CANCER BIOLOGY AND THE CHANGING THERAPEUTIC LANDSCAPE

Chair: Sheila A. Stewart, Washington University,
St. Louis, MO

Tony Hunter, Salk Institute, La Jolla, CA

William G. Kaelin, Jr., Dana-Farber Cancer Institute,
Boston, MA

Olufunmilayo I. Olopade, University of Chicago
Medicine Comprehensive Cancer Center, Chicago, IL

Dennis J. Slamon, UCLA David Geffen School of
Medicine, Los Angeles, CA

Wednesday, April 14, 2021

LEVERAGING THE IMMUNE SYSTEM IN THE WAR ON CANCER

Chair: Nina Bhardwaj, Icahn School of Medicine at
Mount Sinai, New York, NY

Anjana Rao, La Jolla Institute for Immunology,
La Jolla, CA

Sergio A. Quezada, University College London Cancer
Institute, London, United Kingdom

Michel Sadelain, Memorial Sloan Kettering Cancer
Center, New York, NY

Additional speaker to be announced.

MAJOR SYMPOSIA

AACR-Bayard D. Clarkson Symposium on Stem Cells,
Leukemia, and the Niche

Advances in Cancer Nanotechnology

Alternative DNA Repair Pathways and Their
Drug Targets

Artificial Intelligence in Cancer Imaging

Artificial Intelligence/Machine Learning in Cancer
Research and Care: Progress and Opportunities

Cancer Immunometabolism

Colorectal Cancer Interception: Immunologic and
Pharmacologic Advances

COVID-19 and Cancer Research

Cytokine Receptors in Immuno-oncology:
Discovery, Analysis, and Modulation

Deubiquitylating Enzymes as Targets for Cancer
Therapy

Developing Rational Combinations of Targeted Drugs

Diet, Clock, and Cancer

Drugging KRAS

Engineering and Modulating Natural Killer Cells for
Cancer Immunotherapy

Familial Predisposition: Precision Medicine and
Targeted Therapy

From 'Omics Data to Prognostic and Predictive
Biomarkers

Functional Precision Medicine in Cancer

Germline Influence on Immunotherapy Outcomes

Implications of Clonal Hematopoiesis in Human Health

Improving Therapy through Normalization of the
Tumor Microenvironment

Matrix, Exosomes, and TME Cells in the Metastatic
Niche

Mechanisms and Biomarkers of Response and
Resistance to Immunotherapy

Metabolism and Chromatin Dereglulation in
Cancer and Cancer Heterogeneity

Modeling Metastatic Progression in the Mouse

Molecular Imaging

Neoadjuvant Immunotherapy for Melanoma and
Other Cancers

AACR ANNUAL MEETING 2021
SCIENTIFIC PROGRAM

Major Symposia (*cont'd*)

New Approaches to Chimeric Antigen Receptor Engineering

New Combinations of Targeted Therapies and Immunotherapies

Next Frontiers in Adjuvant Therapy

Next-Generation Epigenetic Drugs

Options and Opportunities for Treating Metastasis

Paracrine Signaling in Cancer

Phase Separation, Transcription, and Cancer

Progress from Personalized Cancer Vaccine Trials

T Cells in Cancer

The Cancer Dependency Map

The Clinical Proteomic Tumor Analysis Consortium: Building a Proteogenomic Atlas of Cancer

The Microbiome in Cancer Therapy: Hype or Hope?

The Tumor Microbiome and Its Role in Oncogenesis and Modulating Therapy Response

Toward Engineering of Neoantigen-Specific T-Cell Therapies

Tumor Cell Plasticity and Resistance to Cancer Therapies

Tumor Hypoxia and Genetic Instability: New Mechanisms and New Targets

When Is Transforming Growth Factor Beta Targetable?

AACR-ASCO Joint Session: Targets in the Treatment of Renal Cell Cancer

AACR-CSCO Joint Symposium: Single-Cell Analysis—Changing the Landscape of Cancer Research

AACR-JCA Joint Session: Tracking Tumor Evolutionary Dynamics: From Initiation through Metastasis

AACR-ONS Special Session: Symptom Science

ADVANCES IN DIAGNOSTICS AND THERAPEUTICS

Advances in Drug Delivery

Computational Methods for Immunogenomics and Precision Oncology

Diagnostic Tests for Immunotherapy: Current CLIA Lab Testing and Future Directions

DNA Damage Response (DDR) Treatment: Evolving Diagnostic Approaches, Understanding of Replication Stress, and Resistance Mechanisms to DDR Targeting Therapies

Hybrid Technologies for Cancer Imaging, Theranostics, and Image-Guided Interventions

Management of Toxicity of Immune Cell Therapy

Noninvasive Monitoring of Minimal Residual Disease with Liquid Biopsies: Toward Real-Time Treatment Decision-Making

Proton Therapy and FLASH Irradiation

Targeting Transcriptional Cyclin-Dependent Kinases in Cancer

Translational Canine Models Advancing Immunotherapy and Immunogenomics

Understanding and Overcoming Resistance to Third Generation EGFR and ALK Inhibitors

ADVANCES IN ORGAN SITE RESEARCH

Advances in Endometrial Cancer

Advances in Sarcoma Therapy

Developing More Effective Treatments for Triple-Negative Breast Cancer

Diffuse Large B-Cell Lymphoma

Emerging Concepts in Liver Cancer Research

Next-Generation Treatments for Melanoma: Building on Success

Pathways to Early Detection of Pancreatic Cancer

Solid Tumor Brain Metastasis

Targeting Signaling Pathways in Colorectal Cancer

Therapeutic Advances in Biliary Tract Cancers

Therapeutic Vulnerabilities and Resistance Mechanisms in Estrogen Receptor-Positive Breast Cancer

ADVANCES IN PREVENTION, EARLY DETECTION, AND INTERCEPTION

Connecting the Tumor Microenvironment with the
Macroenvironment in Cancer Cachexia

Interception of Preneoplasia

Molecular Targets of Precision Prevention and
Interception

Panel on Rural Cancer Control

Radiation-Induced Cancers and Cancer Survivorship

ADVANCES IN THE SCIENCE OF CANCER HEALTH DISPARITIES

Carcinogenic Exposures and Global Cancer Prevention

Pan-Cancer Distinctions in Tumor Biology across
Ethnicity and Genetic Ancestry

Precision Medicine in Underserved Populations

FORUMS

Are Antitumor T Cells Exhausted or Dysfunctional?
Does It Matter?

Are There Cancer Stem Cells?

Biostatistics Debate: Should Science Be Guided by
P-Values?

Cancer Cell Dormancy: The Current Paradigm and the
Challenges Ahead to Develop New Therapies

CAR T-Cell Therapy or T-Cell Engager?

Data Science and Machine Learning: Will They
Revolutionize Cancer Cure and Research?

Embracing Entrepreneurship in Cancer Research

Microbiome Pandemonium: Checkpoints and
the Microbiome

Patient-Derived Models for Cancer

The Myths and Realities of the Abscopal Effects

What Is the Role for Oncolytic Viruses in Cancer
Treatment?

EDUCATIONAL PROGRAM: EDUCATIONAL SESSIONS AND METHODS WORKSHOPS

Educational programming will begin on Friday, April 9, at 3:00 p.m. and continue through 3:30 p.m. on Saturday, April 10. The Educational Program is an integral part of the meeting and provides attendees with an opportunity to expand their knowledge base. Meeting registrants will be able to purchase an Educational Program Pass granting access to the complete educational program of more than 65 unique sessions covering all areas of cancer research, including the popular multisession programs noted below. More information about the Educational Program and the Educational Program Pass will be available at AACR.org/AACR2021.

- ★ Tumor Immunology and Immunotherapy for Nonimmunologists. Annually, this two-part series combines a comprehensive review of a hot topic in the field with a roundtable session that enables attendees to participate in group discussions with leading experts in the field.
- ★ Chemistry to the Clinic. This three-part series provides attendees with foundational knowledge of critical elements of the drug development process, such as lead optimization, identification of targets, and drug modalities.
- ★ Clinical Trial Design. Over the course of three consecutive sessions, this Methods Workshop will provide attendees with a historical and methodologic understanding of clinical trials and demonstrate how to design an appropriate trial to answer the scientific questions presented by emerging treatments.

Additional details will be posted at
AACR.org/AACR2021.

AACR ANNUAL MEETING 2021

POLICY SESSIONS



Decisions made by policymakers in Washington, DC, have a direct impact on cancer research and the progress being made against cancer in the United States and throughout the world. The AACR sponsors sessions with policymakers, academic researchers, patient advocates, cancer survivors, and industry representatives to foster dialogue about emerging topics in science and health policy, and regulatory science and policy.

The **Science and Health Policy Track** includes sessions that will provide attendees with an opportunity to learn about how policy impacts science and vice versa. Science policy sessions will examine the current political environment affecting federal funding for the NIH and NCI, including highlighting ways for scientists to get involved in advocating for robust, sustained, and predictable budget increases. Health policy sessions will explore how scientific evidence can inform policy on cancer prevention and control and what impact policies are having on patients and communities. Past health policy sessions have covered topics such as e-cigarettes and tobacco control measures, the Affordable Care Act, and ways to prevent and control pathogen-related cancers, such as increasing the use of the human papillomavirus (HPV) vaccine.

The **Regulatory Science and Policy Track** includes informative sessions designed to highlight recent regulatory developments and provide an open forum for the consideration of issues that the FDA faces as the agency seeks to accelerate the pace of approval of safe and effective treatments for patients with cancer. These sessions offer an opportunity for attendees to discuss cutting-edge issues in cancer drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and government. Past regulatory science and policy topics have included strategies for increasing participation of underrepresented populations in clinical trials, guidance for using real-world evidence to support clinical trials during the COVID-19 pandemic, regulatory considerations for developing liquid biopsy tests, implications of site-agnostic therapy approval for drug development, and applications for artificial intelligence/machine learning in regulatory decision-making.

The **Science of Survivorship Track** includes sessions highlighting new and high-value areas of research to address the array of challenges facing long-term cancer survivors. Sessions invite trans-sector discussion among the survivor and advocacy communities, basic and clinical researchers, industry representatives, health care providers, and government officials. Past science of survivorship topics have included aging and cancer, long-term survivorship and vulnerable populations, development of new survivorship models, patient-reported outcomes, data sharing, and patient engagement.



SUBMIT YOUR CLINICAL TRIALS ABSTRACTS TO THE AACR ANNUAL MEETING 2021

Become a part of our growing clinical research program at the Annual Meeting and help us showcase how discovery science continues to transform the lives of cancer patients.

WHY YOU SHOULD SUBMIT

- ★ Numerous and unique oral presentation opportunities
 - Four Clinical Trials Plenary Sessions offering companion presentations discussing the science behind the trials presented
 - Three Clinical Trials Minisymposia
- ★ Poster presentations (enhanced e-Posters with opportunities for engagement)
- ★ Opportunities for extensive national media coverage through the AACR press program
- ★ Opportunities to simultaneously present your work and publish a manuscript in a high-impact AACR journal
 - Indicate your intention to submit a manuscript during the abstract submission process.
 - Contact pubs@aacr.org with any questions.
- ★ No restrictions on presenters if the presentation is CME-compliant

WHAT TO SUBMIT

- ★ Any phase (I, II, III, or any combination) abstract from national or international clinical trials
- ★ Promising ongoing trials, or unique trial designs that have not yet yielded results, to the Clinical Trials in Progress category (CT08)
- ★ Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the previous presentation (as determined by the review committee).
- ★ COVID-19 and cancer clinical trials to the COVID-19 and Cancer (COVID06) or Clinical Trials (CT07) categories.
- ★ See pages 21-22 for clinical trials (CT) abstract categories and visit [AACR.org/AACR2021](https://aacr.org/AACR2021) for submission guidelines.

WHEN TO SUBMIT

- ★ Submit your completed or placeholder abstract(s) by the January 11, 2021 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 19, 2020 deadline.
- ★ Final results and conclusions for placeholder abstracts are due by February 4, 2021.

AACR VIRTUAL ANNUAL MEETINGS I AND II 2020

30

TRIALS IN CLINICAL
PLENARY SESSIONS

104

TRIALS IN
POSTER SESSIONS

50

TRIALS IN PROGRESS
IN POSTER SESSIONS

PROFESSIONAL ADVANCEMENT OPPORTUNITIES



In support of its mission to promote the education and training of cancer scientists and clinicians and to cultivate a highly skilled and diverse cancer research workforce, the AACR provides Annual Meeting attendees at all career stages—from high school and undergraduate students to senior investigators—with opportunities to enhance and advance their careers. For more information about any of the professional development opportunities that follow, visit AACR.org/AACR2021 and click on the “Professional Development Opportunities” tab.

NEXTGEN STARS

Early-career scientists can apply to give a presentation in a Major Symposium or Advances Session at the AACR Annual Meeting 2021. Speaking slots are limited and are only available to AACR Associate Members and to AACR Active Members who are not above the level of assistant professor or equivalent. The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career scientists at the AACR Annual Meeting and to support the professional development and advancement of those selected to speak.

The deadline to submit applications is **12:00 p.m. U.S. ET, October 13, 2020**. Applications consist of an extended abstract (limit 8,000 characters), a CV, and a letter of recommendation from a P.I., department head, or another mentor who is familiar with the applicant’s work. Applicants selected as NextGen Stars for 2021 will receive travel support and complimentary registration for the meeting. Details can be found at AACR.org/AACR2021 under the “NextGen Stars” tab.

PROFESSIONAL ADVANCEMENT SESSIONS

Exclusive Member Benefit

Professional Advancement Sessions have long been an integral part of the AACR Annual Meeting experience, representing the AACR’s dedication to the education, training, and career advancement of cancer research investigators at all stages of their careers. Each year, several interactive and engaging professional development and career advancement opportunities are organized to provide important skills to investigators at all levels, from students to senior faculty.

All Professional Advancement Sessions are free and exclusive to AACR members. There is no cost to join the AACR as a Student Member (high school students and undergraduates) or Associate Member (graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to a career in cancer research). If you are not an AACR member, you are strongly encouraged to join and take advantage of being able to attend these sessions and the many other benefits of membership, including the privilege of sponsoring abstracts, and reduced member registration rates for the Annual Meeting 2021. Visit AACR.org/Membership to apply today!

Professional Advancement Sessions to be held at the Annual Meeting 2021 will be announced in the fall. Visit AACR.org/PAS for session updates, including opportunities for physician-scientists and early-career and early-stage investigators.

CONTINUING MEDICAL EDUCATION (CME)



The AACR's Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status by the Accreditation Council for Continuing Medical Education (ACCME). The AACR CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advancing the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. The AACR Annual Meeting 2021 will be a Continuing Medical Education Activity and *AMA PRA Category 1 Credits™* will be available. This is a great opportunity to complete your required credit hours.



MEET YOUR MOC POINT REQUIREMENTS

If you are a physician, you can meet your Maintenance of Certification (MOC) point requirements at the AACR Annual Meeting 2021. The meeting is CME/MOC accredited. Successful completion of the CME activity enables you to earn MOC points of the American Board of Internal Medicine's (ABIM) Maintenance of Certification program.

SURVIVOR AND PATIENT ADVOCACY PROGRAM



AACR'S COMMITMENT TO SURVIVORS AND PATIENT ADVOCATES

The voices of patients with cancer have never been more important than in today's environment, especially as patients are partnering with researchers by selflessly donating tissue and personal data to advance progress. Additionally, patient advocates play a crucial role in educating the public about new research discoveries, serving on committees and panels to inform cancer research and regulatory policies, increasing awareness among legislators, and raising precious funds for cancer research.

The AACR recognizes and celebrates the contributions of survivors and patient advocates to cancer research and policy and welcomes their attendance and participation at the AACR Annual Meeting.

Discounted registration rates are available for patient advocates.

AACR SCIENTIST ↔ SURVIVOR PROGRAM

A special advocacy program that the AACR hosts each year is the AACR Scientist ↔ Survivor Program (SSP), which is now in its 23rd year. Led admirably since its inception by Anna D. Barker, PhD, of the Lawrence J. Ellison Institute for Transformative Medicine of USC, SSP is designed to build enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide. The program has a competitive application process and occurs twice each year, with the larger program being held in conjunction with the AACR Annual Meeting.

This unique program provides an opportunity for patient advocates to learn about cancer research and to interact with scientists, physicians, health care professionals, and other advocates.

Specifically, patient advocate representatives come together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures in lay terms; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

If you are interested in applying for this year's SSP, please visit [AACR.org/SSP2021](https://aacr.org/SSP2021) or contact us at advocacy@aacr.org.

Patient advocates can also engage with the AACR in many ways throughout the year, including through AACR's magazine *Cancer Today*, the AACR Foundation, the annual *AACR Cancer Progress Report*, and by participating in advocacy days on Capitol Hill.



ATTRACTING JOURNALISTS WORLDWIDE, GENERATING MAJOR NEWS COVERAGE

The AACR is the authoritative resource and voice for cancer research, and the AACR Annual Meeting garners the best in national and international news coverage. The AACR Virtual Annual Meetings I and II, held in April and June 2020, attracted a total of 174 registered reporters. The two meetings showcased innovative clinical, translational, and basic research and generated nearly 2,500 media clips in leading consumer and trade outlets including The Associated Press, *The New York Times*, *The Washington Post*, Reuters, STAT, and *Science*, among many others.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2021 press program. For more information on the AACR Annual Meeting press program, please contact Julia Gunther at julia.gunther@aacr.org or Rick Buck at rick.buck@aacr.org.

UTILIZING SOCIAL MEDIA TO AMPLIFY THE CONVERSATION

The AACR Virtual Annual Meetings I and II 2020 also generated significant social media activity in the cancer research community. Social media highlights included:

AACR Virtual Annual Meeting I 2020:

2,758

PEOPLE JOINING THE CONVERSATION ON TWITTER

9,003

TOTAL TWEETS USING THE #AACR20 HASHTAG

45,427,000

TOTAL IMPRESSIONS

AACR Virtual Annual Meeting II 2020:

2,307

PEOPLE JOINING THE CONVERSATION ON TWITTER

7,065

TOTAL TWEETS USING THE #AACR20 HASHTAG

42,426,000

TOTAL IMPRESSIONS



Through the generosity of its loyal supporters and grants from the National Cancer Institute (NCI), the AACR is pleased to provide financial support to meritorious undergraduate students and early-career scientists residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Detailed information about these award programs, including eligibility and selection criteria, can be found by visiting [AACR.org/AACR2021](https://www.aacr.org/AACR2021) and clicking on the “Financial Support for Attendance” link.

AACR SCHOLAR-IN-TRAINING AWARDS

Exclusive Member Benefit

Scholar-in-Training Awards are available for Associate Members in good standing who are the presenters of meritorious abstracts at the AACR Annual Meeting. These awards are made possible by the generosity of supporting foundations and corporations. Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a Scholar-in-Training Award should submit their AACR membership applications by **November 12, 2020**. The AACR Membership Application Form is available on the AACR website at [AACR.org/Membership](https://www.aacr.org/Membership). To apply for a Scholar-in-Training Award, an applicant must first submit an abstract, and then complete a separate award application. For details of the application process and the selection criteria, please visit [AACR.org/SITA](https://www.aacr.org/SITA). Application deadline: **November 19, 2020**.


AACR GLOBAL SCHOLAR-IN-TRAINING AWARDS

Global Scholar-in-Training Awards (GSITA) of \$2,000 are available for eligible early-career investigators in countries building cancer research capacities. Applicants must submit an abstract to the AACR Annual Meeting 2021 and then complete a separate GSITA application. Applicants must be Associate Members of the AACR in good standing (membership current through 2020). Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a GSITA should submit a Membership Application Form by **November 12, 2020** before submitting their GSITA application. For additional details and a list of eligible developing countries, visit [AACR.org/GSITA](https://www.aacr.org/GSITA). Application deadline: **November 19, 2020**.

AACR-MINORITIES IN CANCER RESEARCH (MICR)-SPONSORED AWARDS

Minorities in Cancer Research (MICR)—a membership group within the AACR—is working to increase the number, participation, visibility, and recognition of minority scientists in cancer research. The AACR Minority and Minority-Serving Institution Faculty Scholar Awards and Minority Scholar Awards are two of several programs sponsored by MICR in support of its mission. These awards are generously supported by the NCI Center to Reduce Cancer Health Disparities. To learn more, please visit [AACR.org/MICR](https://www.aacr.org/MICR) or send an email to micr@aacr.org.

AACR Minority and Minority-Serving Institution (MMSI) Faculty Scholar in Cancer Research Awards: Full-time minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer



AACR ANNUAL MEETING 2021 FINANCIAL SUPPORT FOR ATTENDANCE *(cont'd)*

Health Disparities of the NCI, the purposes of these awards are to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. For details or to submit an application, visit [AACR.org/MSI](https://aacr.org/MSI). Application deadline: **November 19, 2020.**

AACR Minority Scholar in Cancer Research Awards: Presenters of a proffered paper who are full-time predoctoral (graduate or medical) students, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field are encouraged to apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the NCI, this program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research, e.g., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. For details or to submit an application, visit [AACR.org/MSA](https://aacr.org/MSA). Application deadline: **November 19, 2020.**

AACR-WOMEN IN CANCER RESEARCH (WICR) SCHOLAR AWARDS

The AACR-Women in Cancer Research (WICR) Scholar Award is a highly competitive award recognizing WICR members who are scientists-in-training and presenters of meritorious scientific papers at the AACR Annual Meeting. The purpose of this award is to increase the scientific knowledge base of WICR members and to encourage them to pursue careers in cancer research. All graduate students, medical students, residents, clinical fellows, and postdoctoral fellows are welcome to apply. For details or to apply, visit [AACR.org/WSA](https://aacr.org/WSA). Application deadline: **November 19, 2020.**

“Excellent organization and presentation of talks.
Delivery of talks was well orchestrated!”

GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS



AACR Abstract Submission System. Authors must submit abstracts for presentation at the Annual Meeting 2021 using the AACR Abstract Submission System, which will be available at AACR.org/AACR2021 beginning September 30, 2020. You can create, modify, and submit abstracts until the November 19, 2020, abstract deadline. Complete instructions on the use of the AACR Abstract Submission System will be provided on the website.

Note for 2021: Submit your abstract detailing how you use AACR Project GENIE data by the November 19, 2020, deadline for an opportunity to be featured in a special session during the Annual Meeting 2021. Simply include GENIE as a keyword during the submission process.

The Abstract Submission System has been optimized for the current versions of most browsers:

- ★ **Google Chrome:** Version 23.0 or higher
- ★ **Internet Explorer:** Version 9.0 or higher
- ★ **Mozilla Firefox:** Version 27.0 or higher
- ★ **Safari:** Version 7.1 or higher
- ★ **Microsoft Edge:** Version 79.0 or higher

Browsers should be set to enable JavaScript and to accept cookies. Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or aacr@support.ctimeetingtech.com.

Responsibilities of Authors. By submitting an abstract for presentation at the AACR Annual Meeting, abstract authors agree and/or attest to the following:

★ **Support for Abstract/Verification of Authorship.**

All authors accept individual responsibility for the accuracy and integrity of statements in their abstract, and the submitting author is required to ensure that all authors have confirmed that all statements are an accurate reflection of the presented data and have agreed to the submission of the abstract and to their being listed as contributors prior to submission. Authors will be notified of their inclusion on an abstract via email.

- ★ **Sponsorship of Abstracts.** The submitting author must provide the name of an AACR member who has agreed to sponsor the abstract, and the submitting author must attest that the permission of the member sponsor has been secured prior to initiating an abstract submission. See page 18 for Abstract Sponsorship Regulations.

- ★ **Transfer of Copyright.** On behalf of all authors, the submitting author must assign and transfer copyright for the abstract to the AACR.

- ★ **Presentation of Abstracts.** The submitting author for each abstract must designate a presenter who agrees to register for the meeting and attend the corresponding session to discuss in detail the research presented in the published abstract. If the assigned presenter cannot attend the meeting, the authors are expected to designate a replacement or withdraw the abstract (see page 17).

- ★ **Confirmation of No Prior Publication/Presentation.** Authors who submit an abstract confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2021.

Exception: Encore presentations are permitted for clinical trials abstracts that are submitted for the January 11, 2021, clinical trials deadline. During the submission process, authors of encore clinical trials abstracts must provide the date and name of the meeting at which the original trial abstract was presented.

- Content of Abstracts.** Each abstract should contain (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition* (Council of Science Editors, 2014).

- Abstract Control Number.** An Abstract Control Number (e.g., 21-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

- Financial Relationships of Coauthors.** Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships

AACR ANNUAL MEETING 2021 GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS (cont'd)

of each of your coauthors. For more information on financial relationships, visit [AACR.org/CME](https://www.aacr.org/CME).

Sponsor Permission and Information. Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, see the “Abstract Sponsorship Regulations” on page 18.

Length of Abstracts. The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

Abstract Category, Subcategory, and Subclassification. You must select a category, subcategory, and subclassification for your abstract. See pages 19-23 for details.

Disclosure of Chemical Structures. At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids cocrystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required.

The Program Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts without chemical structures may be accepted for presentation if deemed to be of sufficient scientific merit.

Submission Fee. Each abstract submitted must be accompanied by a **\$65 abstract submission fee**. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.

Abstract Deadline. The deadline for abstract submissions is **11:59 p.m. U.S. ET, Thursday, November 19, 2020**. Abstracts submitted after the deadline will not be considered by the Program Committee. **No significant changes may be made to**

abstracts after the November 19, 2020, deadline.

Note: Submitting an abstract for presentation at the AACR Annual Meeting 2021 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting at [AACR.org/AACR2021](https://www.aacr.org/AACR2021).

Late-Breaking Abstract Deadline. The deadline for late-breaking abstracts is **11:59 p.m. U.S. ET, Monday, January 11, 2021**. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted.

Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.

Clinical Trials Abstract Deadline. All abstracts describing clinical trials (including placeholder abstracts) should be submitted as late-breaking abstracts. The deadline for clinical trials abstracts is **11:59 p.m. U.S. ET, Monday, January 11, 2021**. Final data for placeholder abstracts are due **Thursday, February 4, 2021** (see page 9). Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts.

Publication Opportunity. For consideration of simultaneous publication in an AACR journal, please contact the AACR Publishing Division at pubs@aacr.org.

Presentation of Proffered Papers at the AACR Annual Meeting. Every proffered abstract that has been accepted for publication in the online *Proceedings* must have a corresponding presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must attend the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. Presentation formats for 2021 include ePosters with enhanced engagement and networking opportunities and short talks in minisymposia. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the paper, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no abstract authors are available to present the data, the presenter must withdraw the abstract immediately by contacting the AACR Program Development Department at 215-440-9300 or abstractchanges@aacr.org. Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:

- ★ The withdrawal of the abstract from the session
- ★ The removal of the abstract from the online *Proceedings*
- ★ The loss of future sponsorship privileges for the sponsor of the abstract
- ★ The loss of future abstract submission/authorship privileges for the presenter of the abstract

Deadline for Withdrawal of Abstracts. Requests to withdraw regular abstracts will be accepted through **Monday, February 22, 2021**. Requests to withdraw late-breaking or clinical trials abstracts will be accepted through **Tuesday, March 9, 2021**. Withdrawal requests must be sent by email to abstractchanges@aacr.org. Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal.

ABSTRACT SPONSORSHIP REGULATIONS

Expanded Abstract Sponsorship Privileges for AACR Members

Expanded abstract sponsorship privileges for selected AACR member types are available for the AACR Annual Meeting 2021, as outlined below:

- ★ **Active, Honorary, and Emeritus Members** may now sponsor an **unlimited number of abstracts** for presentation at the meeting. (As always, members must verify the content, authenticity, and quality of the abstracts they agree to sponsor.)
- ★ **Affiliate Members** are still permitted to sponsor one abstract for each deadline provided that they are the presenter of the abstract. However, Affiliate Members are **no longer required to provide an endorser** for their abstract.

Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 19 regular abstract deadline, member dues must be paid in full through 2020. To be in good standing for the January 11 late-breaking and clinical trials abstract deadline, member dues must be paid in full through 2021. Associate, Honorary, and Emeritus Members are exempt from the payment of dues; therefore, this regulation does not apply to them.

1. Each abstract submitted for presentation at the AACR Annual Meeting must be sponsored by an Active, Emeritus, Honorary, Affiliate, or Associate


AACR Member in good standing. (Student members are not eligible to sponsor an abstract.)

2. An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or her sponsorship privileges in two ways: (a) to sponsor abstracts on which he or she is listed as an author, or (b) to sponsor abstracts submitted by colleagues on which he or she is not listed as an author.
3. An Associate Member in good standing may sponsor one abstract for each submission deadline provided that (a) he or she is the presenter of the abstract, and (b) an Active, Emeritus, or Honorary Member in good standing endorses the work. Active, Emeritus, and Honorary Members may endorse an unlimited number of abstracts while still retaining their right to sponsor an unlimited number of abstracts.
4. An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. (Affiliate Members are no longer required to provide an endorser.)
5. Permission to list an AACR member as a sponsor or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Submission System. Individuals listed as sponsors or endorsers of abstracts will receive a notification of sponsorship or endorsement via email.
6. The sponsor must verify the content, authenticity, and quality of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE AUTHORS. Adherence to these rules will be strictly enforced. Violations will result in the rejection of the abstract by the Program Committee.

MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP

Nonmember individuals interested in joining the AACR and sponsoring an abstract for Annual Meeting 2021 must submit an application for membership no later than **November 12, 2020**. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than **January 7, 2021**. Membership questions may be directed to membership@aacr.org.



The 2021 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2021. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. **The regular abstract submission deadline is Thursday, November 19, 2020 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is Monday, January 11, 2021 (11:59 p.m. ET).**

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequalities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, a new submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.

MCB Molecular and Cellular Biology, Genetics

MCB01 Cell Growth Signaling Pathways

Cell signaling
Cell-cell interactions
Growth factors
GTPases, their regulators, and effectors
Kinases and phosphatases
Receptors
Tumor-stromal cell interactions
Ubiquitin and ubiquitin-like proteins
Other

MCB02 Cell Death

Apoptosis
Autophagy
Bcl-2 family proteins
Caspases
Effectors of apoptosis
Inhibitor of apoptosis (IAP) family proteins
Necrosis and necroptosis
Transcriptional control of apoptosis
Other

MCB03 Oncogenes and Tumor Suppressor Genes

Cytoplasmic signal transducers
Genotype/phenotype correlations
Nuclear oncoproteins and tumor suppressor genes
Oncogene growth factors and their receptors
Tumor suppressor genes
Other

MCB04 Gene Regulation and Transcription Factors

Chromatin structure and function
Gene expression
Mechanisms of transcription
Oncogenic transcription factors
Posttranscriptional and translational control
Promoters and enhancers of transcription
Protein-protein interactions in transcription factor function

Regulation of transcription factor function
Transcriptional control of cell differentiation
Other

MCB05 Epigenetics

Chromatin structure and function
DNA methylation
Epigenetic changes as molecular markers of cancer
Epigenomics
Gene silencing
Histone modification
Other

MCB06 Cell Cycle

CDKs and CDK inhibitors
Cell cycle checkpoints
Control of cell cycle progression
Mitosis
Telomeres and telomerase
Other

MCB07 DNA Damage and Repair

Chromosomal structural alterations/translocations
Genomic instability
Homologous recombination
Mechanisms of genomic alterations
Radiation-induced DNA damage
Other

MCB08 Metabolism and Cancer

Metabolic pathways
Metabolomics
Mitochondrial function
Signaling pathways that regulate metabolism
Warburg effect
Other

MCB09 Genomics

(See also BSB01: Bioinformatics and Computational Biology)
Functional genomics
Genomic profiling of tumors
High-throughput sequencing

Large-scale approaches to cancer gene discovery
Microarrays
Other

MCB10 microRNAs and Other Noncoding RNAs

Epigenetic control of miRNA expression
miRNA profiling in cancer
miRNA regulation of cancer biology
miRNA-based diagnostics
miRNA-based therapeutics
miRNAs as tumor suppressors/oncogenes
Noncoding RNAs
Other

MCB11 Cellular Stress Responses

Hypoxia
Oxidative stress
Senescence
Unfolded protein response
Other

BSB Bioinformatics, Convergence Science, and Systems Biology

BSB01 Bioinformatics and Computational Biology

(See also MCB09: Genomics)
Analytic pipeline optimization
Application of bioinformatics to cancer biology
Database resources
Molecular modeling
New algorithms
New software for data analysis
Sequence analysis
Statistical methods
Other

BSB02 Convergence Science and Systems Biology

Artificial intelligence and machine learning
Integrative cancer biology
Mathematical modeling
Network biology
Physical sciences and engineering
Systems engineering
Other

TB Tumor Biology

TB01 Nonclinical Models of Cancer

3-D and tissue recombinant models
Developmental phenotypes of cancer genes
Human-in-mouse models of human cancer
Model organisms in drug discovery
Mouse models of human cancer
Noninvasive imaging in animal models
Organoids
Patient-derived xenograft models
Zebrafish models of cancer
Other animal and cell models of cancer
Other

TB02 Stem Cell Biology

Adult stem cells
Cancer stem cells
Developmental pathways in cancer
Embryonic stem cells
Stem cell markers
Stem cells and regenerative medicine in oncology
Other

TB03 Tumor Adhesion

Cell adhesion and extracellular matrix
Cell-cell adhesion
Drug resistance
Other

TB04 Invasion and Metastasis

Actin cytoskeleton
Biomarkers of metastasis
Epithelial/mesenchymal transition (EMT and MET)
Expression profiling of tumor progression and metastasis
Genes that regulate migration and invasion
Imaging of tumor progression and metastasis
Invasion and migration
Metastasis suppressor genes
Metastasis-promoting genes
Premetastatic niche
Therapeutic metastasis prevention
Other

TB05 Angiogenesis

Angiogenesis and angiogenesis inhibitors
Host-tumor interactions
Molecular mechanisms of angiogenesis
Novel pro- and antiangiogenic factors
Tumor microcirculation and the microenvironment
Other

TB06 Tumor Microenvironment

Chemokines in the microenvironment
Drug targets in the microenvironment
Extracellular matrix and integrins
Gene expression in the microenvironment
Immune cells in the tumor microenvironment
Immunity and the microenvironment
Inflammatory cells as regulators of tumor growth
Microbiome
Organ-specific microenvironments
Proteases and inhibitors in the microenvironment
Tumor dormancy
Tumor/stromal interactions
Tumor-immune system interactions
Other

TB07 In Vivo Imaging

(See also CL01: Translational Research – Molecular Biology in the Clinic)

Advanced nanotechnology and imaging
Application of imaging technology to the clinic
Imaging in animal models
Imaging of molecular and cellular events in the tumor microenvironment
Imaging of molecular and cellular events in tumors and tumor cells
Imaging the immune response
Imaging tumor metabolism
New targets for imaging
Other

TB08 Pediatric Cancer - Basic Science

(See also CL02: Pediatric Cancer – Clinical Investigations; CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer)

Developmental origins and drivers of pediatric cancer
Pediatric cancer epigenomics and genomics
Pediatric cancer models
Pediatric cancer tumor microenvironment and tumor heterogeneity
Other

TB09 Radiation Science

(See also CL07: Radiation Oncology; ET09: Preclinical Radiotherapeutics)

Modulators of radiation response
Photobiology/photodynamic therapy
Radiation dose fractionation
Radiation-activated signaling pathways
Radiation-induced gene expression
Radiation-induced resistance
Radiobiology research
Radioprotectors and radiosensitizers
Other

TB10 Tumor Evolution and Heterogeneity

Causes and consequences of tumor heterogeneity
Complex adaptive systems
Methods to measure tumor evolution and heterogeneity
Other

TB11 Carcinogenesis

Carcinogenesis: Chemical, environmental, and molecular
Mutagenesis
Tumor initiation and promotion
Viral-induced carcinogenesis
Other

CH Cancer Chemistry

CH01 Drug Discovery, Design, and Delivery

Basic and applied nanotechnology and therapeutics
Cheminformatics, in silico screening, and computational methods
Drug delivery
Drug design
High-throughput screening (assays and libraries)
Lead identification
Lead optimization
Nanotechnology drug delivery
Natural products
Synthesis, metabolism, and disposition
Other

CH02 Structural and Chemical Biology

Chemical genetics and genomics
Nanotechnology in chemical biology
Small molecule, protein, and nucleic acid interactions
Target identification, small molecule probes, and libraries
X-ray and NMR structures
Other

CH03 Proteomics and Mass Spectrometry

Biological mass spectrometry and systems biology
Proteomics and biomarker discovery
Proteomics and signaling networks
Other

ET Experimental and Molecular Therapeutics

ET01 Drug Discovery

Antibody technologies
 Biochemical modulators of the therapeutic index
 Combination chemotherapies
 Differentiation therapy
 New targets
 Novel assay technology
 Novel drug delivery systems
 Targeting the tumor microenvironment in drug development
 Other

ET02 Mechanisms of Drug Action

Cell cycle mechanisms of anticancer drug action
 Cellular responses to anticancer drugs
 Interactions of new agents with radiation
 Role of the microenvironment in therapeutic response
 Other

ET03 Drug Resistance

Drug resistance in molecular targeted therapies
 Drug transport and metabolism
 Novel mechanisms
 Regulation of gene expression in drug resistance
 Reversal of drug resistance
 Other

ET04 Molecular Targets

Cell death pathways and treatment
 Identification of molecular targets
 Modulation of DNA repair
 Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes
 New nonclinical models for targets
 Other

ET05 Pharmacology, Pharmacogenetics, and Pharmacogenomics
 (See also CT01: Phase I Adult Clinical Trials)

Cellular pharmacology
 Molecular pharmacology
 Pharmacogenetics and therapeutic response
 Pharmacogenomics
 Pharmacokinetics and pharmacodynamics
 Preclinical toxicology
 Other

ET06 Small Molecule Therapeutic Agents

DNA-reactive agents
 Epigenetic targets
 HDAC and methyltransferase inhibitors
 Novel antitumor agents
 Novel targets and pathways
 PI3K/AKT inhibitors
 Proteasome inhibitors

Topoisomerases
 Tubulin agents
 Tyrosine kinase and phosphatase inhibitors
 Other

ET07 Biological Therapeutic Agents

(See also CL06: Immuno-oncology; IM02: Immunotherapy, Preclinical and Clinical)

Antireceptors
 Apoptosis: Therapeutic manipulation
 Growth factor receptors and other surface antigens as targets for therapy
 Oncogenes, tumor suppressor genes, and gene products as targets for therapy
 Protein kinases and phosphatases as targets for therapy
 Role of microenvironment in therapeutic response
 Other

ET08 Gene and Vector-Based Therapy

Antisense molecules
 Gene therapy and radiation studies
 Immune modulators
 Vector systems and targeting strategies
 Other

ET09 Preclinical Radiotherapeutics

(See also TB09: Radiation Science; CL07: Radiation Oncology)

Modification of radiosensitivity
 Molecular targets of radiation response
 Normal tissue/cellular stress responses to radiation
 Radioprotectors and radiosensitizers
 Radiotherapeutic combinations
 Other

IM Immunology

IM01 Tumor Immunobiology

Adaptive immunity in tumors
 Epigenetic regulation of tumor immunity
 Inflammation and cancer: Metastasis
 Inflammation and cancer: Tumor initiation and progression
 Innate immunity to tumors
 Microbiome, inflammation, and cancer
 Novel animal models
 Oncogenic pathway-mediated regulation of inflammation and tumor immunity
 Tumor antigenicity/processing and presentation
 Tumor-induced immune suppression: Extrinsic factors
 Tumor-induced immune suppression: Intrinsic factors
 Other

IM02 Immunotherapy, Preclinical and Clinical

(See also CL06: Immuno-oncology; ET07: Biological Therapeutic Agents)
 Adoptive cell therapy
 Combination immunotherapies
 Immune checkpoints
 Immune mechanisms invoked by other therapies including chemotherapy
 Immune mechanisms invoked by radiation therapy
 Immune monitoring/clinical correlates
 Immune response to therapies
 Immunomodulatory agents and interventions
 Inflammation, immunity, and cancer
 Modifiers of the tumor microenvironment
 Therapeutic antibodies, including engineered antibodies
 Vaccines (oncolytic and prophylactic)
 Other

CT Clinical Trials

(including Combination and Immunotherapy Trials)

All clinical trials should be submitted by the January 11, 2021 clinical trials abstract deadline.

CT01 Phase I Adult Clinical Trials

(See also ET05: Pharmacology, Pharmacogenetics, and Pharmacogenomics)

CT02 Phase II Adult Clinical Trials

CT03 Phase III Adult Clinical Trials

CT04 Phase I, II, or III Clinical Trials in Pediatric Cancer

(See also CL02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)

CT05 Phase I, II, or III Clinical Trials in the Elderly

CT06 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

CT07 Clinical Trials for COVID-19
[See also COVID06: Clinical Trials
(Phase I–Phase IV and Trials in
Progress)]

Phase I
Phase II
Phase III
Phase IV, observational, and expanded access
Clinical trials in progress

CT08 Clinical Trials in Progress
Phase I clinical trials in progress
Phase II clinical trials in progress
Phase III clinical trials in progress

CL Clinical Research
[not including clinical trials;
see also the Clinical Trials (CT)
categories]

**CL01 Translational Research – Molecular
Biology in the Clinic**
(See also: TB07: In Vivo Imaging)

Clinical imaging
Cytogenetics and clinical molecular genetics
Epigenetic therapy
Functional and molecular imaging
Laboratory correlates for targeted agents
Molecular classification of tumors
Radiomics
Tumor staging: Correlation of clinical and
molecular markers
Other

**CL02 Pediatric Cancer –
Clinical Investigations**
(See also CT04: Phase I, II, or III
Clinical Trials in Pediatric Cancer;
TB08: Pediatric Cancer – Basic
Science)

Adolescent and young adult oncology
Childhood cancer drug development
Immunotherapeutic approaches to pediatric
cancer
Pediatric cancer predisposition and surveillance
Survivorship, late effects, and secondary
cancers
Therapeutic dosing, resistance, and
combination therapy approaches in
pediatric oncology
Translational pediatric cancer research
Other

CL03 Clinical Research in the Elderly
Aging, immunity, and cancer
Other

**CL04 Clinical Research in Racial and
Ethnic Minorities and Other
Underserved Populations**

Biobanking/biospecimen collection
Clinical trial design
Community engaged research/community-
based participatory research
Patient accrual and retention
Patient navigation
Other

CL05 Biostatistics in Clinical Trials
Design and analysis of clinical trials
New study designs: Theory, methodology, and
modeling
Statistical modeling for cancer studies
Other

CL06 Immuno-oncology
(See also ET07: Biological
Therapeutic Agents; IM02:
Immunotherapy, Preclinical and
Clinical)

Adoptive cell therapy
Combination immunotherapies
Immune checkpoints
Immune mechanisms invoked by other
therapies including chemotherapy
Immune mechanisms invoked by
radiation therapy
Immune monitoring/clinical correlates
Immune response to therapies
Immunomodulatory agents and interventions
Inflammation, immunity, and cancer
Modifiers of the tumor microenvironment
Therapeutic antibodies, including engineered
antibodies
Vaccines (oncolytic and prophylactic)
Other

CL07 Radiation Oncology
(See also TB09: Radiation Science;
ET09: Preclinical Radiotherapeutics)

Clinical radiotherapeutic studies
Interventional radiology
Modification of radiosensitivity
Radiation-immunotherapy and other
radiotherapeutic combinations
Radiation-induced late effects/secondary
cancers
Radiation-induced resistance
Other

**CL08 Surgical Oncology (including
Prophylactic Surgery)**

Surgical oncology

CL09 Clinical Endocrinology
(See also EN01: Molecular,
Preclinical, and Clinical
Endocrinology)

Endocrine-related cancers
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors
Other

**CL10 Survivorship Research and
Supportive Care**

Biology of cell and tissue damage
Comparative effectiveness research and
cost-effective studies
Late effects and second cancers
Psycho-oncology
Supportive care, palliation, and pain
management
Translational survivorship research
Other

CL11 Biomarkers
Biomarkers predictive of therapeutic benefit
Diagnostic biomarkers
Early detection biomarkers
Liquid biopsies: Circulating DNA
Liquid biopsies: Circulating tumor cells
Metastasis biomarkers
Prognostic biomarkers
Other

CL12 Clinical Outcomes Research
Clinical outcomes research

EN Endocrinology

**EN01 Molecular, Preclinical, and
Clinical Endocrinology**
(See also CL09: Clinical
Endocrinology)

Endocrine-related cancers
Growth factors, receptors, and signal
transduction
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors
Other

EP Epidemiology (including Genetic, Molecular, and Integrative Epidemiology)

EP01 Epidemiology

Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects
Biomarkers of prognosis
Cancer health disparities research
Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends
Diet, alcohol, tobacco use, and other lifestyle risk factors
Environmental and occupational risk factors
Familial and hereditary cancers
Functional studies of genetic variants
Gene-gene and gene-environment interactions
Genome-wide association studies (GWAS)/post-GWAS
Health services and comparative effectiveness research
Infection and immune factors
Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)
Pathway and candidate gene studies of risk or prognosis
Pharmacoevidence
Preneoplastic and tumor markers
Primary and secondary intervention studies
Risk prediction models for incidence, prognosis, and/or mortality
Screening and early detection
Statistical and epidemiological methodology
Survivorship research
Other

PR Prevention, Early Detection, and Interception

PR01 Preclinical Prevention, Early Detection, and Interception

Animal models in prevention
Biological and biochemical mechanisms in prevention
Biomarkers and intervention studies
Cellular models
Chemoprevention studies
Diet, nutrition, and cancer
Microbiome and prevention
Molecular markers in prevention research
Molecular targets for prevention
New agent development
Screening and early detection
Other

PR02 Clinical Prevention, Early Detection, and Interception

Application of molecular pathology in clinical prevention
Biomarkers and intervention studies
Cancer health disparities research
Cancer surveillance and screening studies
Chemoprevention clinical trials

Genetic markers as surrogate endpoints in prevention trials
Genomics and proteomics in cancer risk and response assessment
Infections and viral-related cancers
Microbiome and prevention
Prevention and treatment of premalignant lesions (intraepithelial neoplasia)
Prevention of second cancers
Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials
Screening and early detection
Other

PR03 Implementation Science

Behavioral science and prevention
Cancer communication and decision-making
Cancer health disparities research
Genetic testing and counseling
Health policy and outcomes
Obesity, diet, physical activity, and energy balance
Quality of life/late effects/survivorship
Other

COVID COVID-19 and Cancer

COVID01 Intersection of the Biology of SARS-CoV-2 and Cancer

Biomarkers/predictors of COVID-19 and cancer
Host genomics and genetics
Immunobiology
Pathophysiology
Viral evolution
Other

COVID02 Diagnostics for COVID-19 Testing: Design, Development, and Validation

COVID03 Cancer Drug Repurposing to Treat COVID-19

COVID04 COVID-19 Vaccine Development

COVID05 Effects of Cancer Immunotherapies on Patients with COVID-19 (with or without Cancer)

COVID06 Clinical Trials

[See also CT07: Clinical Trials for COVID-19 (Phase I-Phase IV and Trials in Progress)]

Phase I
Phase II
Phase III
Phase IV, observational, and expanded access
Clinical trials in progress

COVID07 Continuity of Cancer Care

Long-term cancer outcomes
Novel health care strategies (including telehealth and digital health)

Palliative care
Patient management
Treatment modifications
Other

COVID08 Effects of COVID-19 on Cancer Survivorship

Long-term health-related quality of life issues
Psychosocial impact on patients and health care workers
Other

COVID09 Risk Factors and Comorbidities Resulting in Adverse Outcomes for Cancer Patients with COVID-19

COVID10 Cancer Prevention and Early Detection during the COVID-19 Pandemic

COVID11 Epidemiology and Registries of COVID-19 and Cancer (including Biorepositories)

COVID12 Health Inequalities and Disparities during the COVID-19 Pandemic

COVID13 Science and Public Policy

Effects of regional public health policies
Funding
Regulatory science and policy
Workforce
Other

RSP Regulatory Science and Policy

RSP01 Regulatory Science and Policy

Biosimilars and generics
Clinical trial design and accrual
Combination therapies and codevelopment of investigational agents and diagnostics
Data science and informatics
Novel endpoints and biomarkers
Real-world evidence and retrospective analyses
Tobacco and e-cigarette regulation
Other

SHP Science and Health Policy

SHP01 Science and Health Policy

Cancer health disparities
Cancer survivorship
Comparative effectiveness research
Implementation science
Patient advocacy and engagement
Value and cost issues in cancer care
Other



AACR MEMBERSHIP: THE ESSENTIAL ASSOCIATION FOR YOU

With over 47,000 members in 127 countries and territories around the world, the AACR is a dynamic and vibrant organization that offers its members opportunities to participate more fully in the global initiative to eliminate cancer. AACR membership is available to those who conduct cancer research and related biomedical science, both senior and early-career investigators, as well as to those health care professionals, research administrators, cancer survivors and advocates, students, and others who share the AACR's vision and support our mission to accelerate the prevention and cure of all cancers.

AACR membership categories promote the professional growth of those in training, facilitate collaborations for established scientists, and provide support for all working in cancer research. Special rates are available to members located in countries with emerging economies as designated by the World Bank. For a complete list of countries with emerging economies, please visit [AACR.org/International](https://www.aacr.org/International).

MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP

Nonmember individuals interested in joining the AACR and sponsoring an abstract must submit an application for membership no later than **November 12, 2020**. Individuals interested in joining the AACR and sponsoring a late-breaking abstract must submit an application for membership no later than **January 7, 2021**.

ABSTRACT SPONSORSHIP

Membership Application Deadlines

November 12, 2020

January 7, 2021

Abstract Deadlines

November 19, 2020

January 11, 2021
(Late-Breaking and
Clinical Trials)

SCHOLAR AWARDS

Membership Application Deadline

November 12, 2020

All Travel Awards Application Deadline

November 19, 2020

Contact the AACR Membership Department with any questions at 215-440-9300 or membership@aacr.org.

AACR MEMBERSHIP CATEGORIES

Active Membership is open to investigators worldwide who have established a record of scholarly activity resulting in original peer-reviewed articles in publications relevant to cancer research and biomedical science.

Affiliate Membership is open to qualified individuals who are health professionals working in support of cancer research and biomedical science; survivors and advocates who are members of organizations whose mission includes the advancement of cancer research; educators; or other professionals who are interested in and/or make substantial contributions to the cancer field.

Associate Membership is open to graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to careers in cancer research and the related sciences. **Annual dues are not required.**

Student Membership is open to persons who have manifested an interest in cancer and the related biomedical sciences and who are enrolled in a program leading to a high school diploma or a bachelor's degree. Annual dues are not required.

Sustaining Membership is open to organizations in recognition of annual payment of dues and other substantial contributions in support of the mission, purposes, and activities of the Association. Annual dues are determined by the Sustaining Member level.

Emeritus Membership is open to existing Active Members who have reached the age of 70 years, who are disabled, or who are retired.

Honorary Membership is open to distinguished individuals who have made extraordinary contributions to the advancement of cancer research either through outstanding personal scientific activity or through exceptional leadership in cancer research. (Candidates for Honorary Membership are invited through a special selection process.)

Please contact the Membership Department at membership@aacr.org or 215-440-9300 and a membership representative will gladly assist with any questions. Not yet a member? Apply for membership at myAACR and join us in the global conquest of cancer.

“The knowledge shared by researchers all around the world helped me in understanding the current landscape of cancer research.”



ABOUT WASHINGTON, DC

Washington, DC, the nation's capital and the political focal point of the country, hosts 176 foreign embassies as well as the headquarters of many international organizations, trade unions, nonprofit organizations, advocacy groups, and professional associations. Home to a lively urban center, Washington, DC, is a walkable city that offers a variety of dining options and numerous free attractions, museums, and historical monuments. The Georgetown Lombardi Comprehensive Cancer Center, the George Washington University Cancer Institute, the National Cancer Institute, the National Institutes of Health, the U.S. Food and Drug Administration, and other government agencies that are important to the cancer field are all located in Washington, DC, and the region.

HOUSING AND REGISTRATION

Housing and registration for AACR Annual Meeting 2021 will open in December. Additional information will be posted at [AACR.org/AACR2021](https://www.aacr.org/AACR2021).

OPPORTUNITIES TO SUPPORT THE AACR FOUNDATION

The AACR Foundation welcomes support from corporations, foundations, individuals, and other organizations that share its mission and are interested in helping to defray the costs of presenting this important international meeting on the latest developments in cancer research. For a complete list of support opportunities and their many benefits, please contact Peter VanPelt, Senior Director, Corporate and Foundation Relations, at 215-446-7256 or via email at peter.vanpelt@aacr.org.

FELLOWS OF THE AACR ACADEMY


The AACR Academy was established in 2013 to honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. Those elected, known as Fellows of the AACR Academy, constitute a global brain trust of individuals who are instrumental in advancing the mission of the AACR to prevent and cure all cancers through research, education, communication, and collaboration.

The AACR Academy is currently led by Dr. Judy E. Garber and a Steering Committee of ten additional Fellows who serve as a voice for all Fellows of the AACR Academy, while providing ongoing advice and counsel to the AACR leadership on timely and significant scientific and policy topics as well as other matters of importance to the cancer field.

The next elected class of Fellows of the AACR Academy will be formally recognized in conjunction with the AACR Annual Meeting 2021 Opening Ceremony scheduled to take place on Sunday, April 11.

AACR SCIENTIFIC ACHIEVEMENT AWARDS, LECTURESHIPS, AND PRIZES

In 1961, the AACR established its first scientific achievement award, partnering with Eli Lilly and Company to present the AACR G.H.A. Clowes Memorial Award. Named for G.H.A. Clowes, a founding member of the AACR and a past research director at Eli Lilly and Company, the award was created to recognize an individual scientist for outstanding recent accomplishments in the field of basic cancer research.



AACR ANNUAL MEETING 2021 GENERAL INFORMATION *(cont'd)*

More than fifty years later, the AACR continues to recognize and reward scientific excellence in all areas of cancer research by annually administering 19 different scientific achievement awards and lectureships. In addition to these awards, the AACR annually presents the AACR June L. Biedler Prize for Cancer Journalism, which since 2015 has recognized outstanding journalistic coverage that enhances the general public's understanding of cancer science and medicine.

All 2020-2021 AACR awardees will be formally recognized throughout the AACR Annual Meeting 2021, with the majority of individuals presenting featured scientific lectures highlighting their research accomplishments. We encourage you to attend these lectures and also to nominate your colleagues for one or more of these prestigious awards at [AACR.org/Awards](https://www.aacr.org/Awards).

SATELLITE EDUCATIONAL SYMPOSIA

Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information will be available at [AACR.org/AACR2021](https://www.aacr.org/AACR2021).

EXHIBIT SHOW

The 2021 AACR Exhibit Show will include a wide array of companies with the latest products and services for laboratory and clinical research. If your organization would like to exhibit and would like to receive an Exhibitor Prospectus, please contact the Exhibits Team at 215-440-9300 or by email at exhibits@aacr.org.

ASSISTANCE FOR PHYSICALLY CHALLENGED REGISTRANTS

The AACR Annual Meeting is accessible to all attendees. Registrants with special requirements for transportation, hotel accommodations, or other facilities connected with the meeting should notify the AACR in advance by checking the appropriate box when registering and providing the necessary details or by emailing the Meetings and Exhibits Department at meetings@aacr.org.

“Exceptional during this unexpected hard time.”
AACR VIRTUAL ANNUAL MEETINGS I AND II
2020



AACR ANNUAL MEETING 2021
COMMITTEES



**AACR ANNUAL MEETING
PROGRAM COMMITTEE**

Chair

Charles Swanton

Vice Chairs

Lewis C. Cantley
Heather R. Christofk
Melissa B. Davis
Keith T. Flaherty
Ricky W. Johnstone
Karen E. Knudsen
Quynh-Thu Le
Jean-Charles Soria
Louis M. Staudt
David A. Tuveson

Cochairs

Peter C. Adamson
Carole L. Baas
Dafna Bar-Sagi
David L. Bartlett
Julie R. Brahmer
Javier Cortés
Riccardo Dalla-Favera
Luis A. Diaz
John F. DiPersio
Steven M. Dubinett
Tariq Enver
Douglas T. Fearon
Irene M. Ghobrial
Anna R. Giuliano
W. Nicholas Haining
James R. Heath
Manuel Hidalgo
Melissa M. Hudson
Stephen D. Hursting
Christine A. Iacobuzio-Donahue
Roger S. Lo
Elli Papaemmanuil
David Pellman
Erik Sahai
Stephen P. Schoenberger
Shelley S. Tworoger
Roel Verhaak
Jane E. Visvader

AACR EDUCATION COMMITTEE

Chair

Roger S. Lo

Additional Appointments Pending

**AACR CLINICAL TRIALS
COMMITTEE**

Cochairs

Julie R. Brahmer
Manuel Hidalgo

Members

Stephen B. Baylin
Joseph N. Contessa
Johann S. de Bono
Stephan A. Grupp
Susan Halabi
Matthew D. Hellmann
Corey J. Langer
Malcolm J. Moore
Kunle Odunsi
Pamela S. Ohashi
Suresh S. Ramalingam
Russell J. Schilder
Yu Shyr
Mark A. Socinski
Roger Stupp
Weijing Sun
Charles Swanton
Dan Theodorescu
Brian Andrew Van Tine
Ignacio I. Wistuba
Stephen Yip

Additional Appointments Pending